LENSAR Reports $13.4 Million Revenue Decline, Achieves Net Income Turnaround

LENSAR, Inc. reported a total revenue of $13.4 million for the three months ended March 31, 2026, a decrease of 5% from $14.2 million in the same period of the previous year. The decline was primarily attributed to a drop in system sales, which fell by 8% to $10.1 million, while service revenue increased by 23% to $1.7 million, reflecting a growing number of system placements. Lease revenue also decreased by 11% to $1.7 million. Despite the revenue decline, LENSAR achieved a net income of $36.3 million, a significant turnaround from a net loss of $27.3 million in the prior year, largely due to a $23.9 million decrease in the change in fair value of warrant liabilities and $10 million in acquisition-related income from a retained cash deposit following the termination of a merger agreement.

The company experienced notable changes in its operational metrics, with an installed base of approximately 440 systems as of March 31, 2026. The total procedure volume increased to 54,094 in the first quarter of 2026, up from 52,347 in the same quarter of 2025. This growth in procedure volume indicates a positive trend in product adoption, despite the overall revenue decline. LENSAR's U.S. sales represented 73% of product and service revenue for the quarter, compared to 55% in the previous year, highlighting a strengthening domestic market presence.

Strategically, LENSAR has focused on expanding its commercial organization, which included approximately 70 commercial professionals as of the end of the first quarter. The company is also pursuing regulatory clearances for its ALLY Robotic Cataract Laser System, which has already received approval in the U.S., India, Taiwan, and South Korea. However, the termination of the merger agreement with Alcon on March 16, 2026, has led to a reassessment of its growth strategy, with the company retaining a $10 million cash deposit as acquisition-related income.

Financially, LENSAR's total assets decreased to $66.2 million as of March 31, 2026, down from $71.4 million at the end of 2025. The company reported current liabilities of $17.8 million, significantly reduced from $40.6 million at the end of the previous year, primarily due to a decrease in accounts payable and accrued liabilities. The company’s cash and cash equivalents stood at $12.5 million, down from $13 million at the end of 2025, indicating a need for careful cash management moving forward.

Looking ahead, LENSAR anticipates continued operating losses and cash outflows in the near term as it invests in the commercialization of its products and navigates macroeconomic challenges, including inflation and supply chain disruptions. The company plans to increase its selling, general, and administrative expenses to support its growth strategy, particularly in expanding its sales and marketing efforts for the ALLY System. LENSAR's future revenue and cash flows will depend on its ability to successfully commercialize its products and secure additional regulatory approvals.